Načítá se...
Pioglitazone for Secondary Prevention after Ischemic Stroke and Transient Ischemic Attack: Rationale and Design of the Insulin Resistance Intervention after Stroke (IRIS) Trial
BACKGROUND: Recurrent vascular events remain a major source of morbidity and mortality after stroke or transient ischemic attack (TIA). The Insulin Resistance Intervention after Stroke (IRIS) trial is evaluating an approach to secondary prevention based on the established association between insulin...
Uloženo v:
| Vydáno v: | Am Heart J |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4254508/ https://ncbi.nlm.nih.gov/pubmed/25458644 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ahj.2014.07.016 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|